US · ARGX · BIOTECHNOLOGY
argenx SE (ARGX) intrinsic value and stock valuation
$925.70as of 2026-11-21 · Mkt cap 53.98B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
argenx SE DCF and intrinsic value
InvestorsCraft values ARGX with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from ARGX’s statements →
argenx SE Graham Number
Graham Number: $238.04d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Regeneron Pharmaceuticals, Inc. (REGN) $920.69
- Cardinal Health, Inc. (CAH) $272.81
- Edwards Lifesciences Corporation (EW) $101.85
- Becton, Dickinson and Company (BDX) $212.78
- IDEXX Laboratories, Inc. (IDXX) $676.21
- Haleon plc (HLN) $9.07
- Agilent Technologies, Inc. (A) $170.38
- Veeva Systems Inc. (VEEV) $266.22
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $4.15B | $2.19B | $1.23B | $410.8M | $1.08B |
| Operating income | $1.05B | -$-21.65M | -$-425.05M | -$-720.34M | -$-348.75M |
| Net income | $1.29B | $833M | -$-295.05M | -$-709.59M | -$-408.26M |
| EPSd | $19.6M | $12.8M | -$-5.16M | -$-13.05M | -$-7.99M |
| Operating cash flow | $850.5M | -$-82.75M | -$-420.33M | -$-862.81M | -$-606.81M |
| Capital expenditure | -$-6.18M | -$-68.3M | -$-43.81M | -$-103.82M | -$-121.43M |
| Free cash flow | $844.3M | -$-151.05M | -$-464.14M | -$-966.63M | -$-728.25M |
| Total assets | $8.68B | $6.2B | $4.54B | $3.13B | $2.85B |
| Total debt | $83.5M | $39.1M | $20M | $12.4M | $11.5M |
| Net debt | -$-3.41B | -$-1.46B | -$-2.03B | -$-788.31M | -$-1.32B |
| Total equity | $7.32B | $5.5B | $4.1B | $2.81B | $2.53B |
| Cash and short-term investments | $4.44B | $3.38B | $3.18B | $2.19B | $2.34B |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $4.15B | $2.19B | $1.23B | $410.8M | $1.08B |
| Cost of revenue | $450.7M | $227.3M | $117.8M | $29.4M | $580.5M |
| Gross profit | $3.7B | $1.96B | $1.11B | $381.3M | $497.3M |
| Research and development expenses | $1.36B | $983.4M | $859.5M | $663.4M | $580.5M |
| Selling, general and administrative expenses | $1.36B | $1.06B | $709.5M | $469.9M | $305.5M |
| Other expenses | -$-75.91M | -$-54.16M | -$-35.5M | -$-31.63M | -$-40.02M |
| Operating expenses | $2.65B | $1.98B | $1.53B | $1.1B | $846M |
| Cost and expenses | $3.1B | $2.21B | $1.65B | $1.13B | $1.43B |
| Interest income | $163.1M | $138.5M | $93M | $24.7M | $3.48M |
| Interest expense | $4.08M | $2.22M | $900K | $2.19M | $1.1M |
| Depreciation and amortization | $28.1M | $17.5M | $111.5M | $104.3M | $5.87M |
| Ebitda | $1.31B | $105.2M | -$-192.28M | -$-622.78M | -$-392.78M |
| Operating income | $1.05B | -$-21.65M | -$-425.05M | -$-720.34M | -$-348.75M |
| Total other income/expenses, net | $224M | $106.8M | $120.6M | -$-8.97M | -$-51M |
| Income before tax | $1.28B | $85.2M | -$-304.5M | -$-729.31M | -$-399.74M |
| Income tax expense | -$-13.43M | -$-747.86M | -$-9.44M | -$-19.72M | $8.52M |
| Net income | $1.29B | $833M | -$-295.05M | -$-709.59M | -$-408.26M |
| Weighted average shares outstanding | $61.3M | $59.9M | $57.2M | $54.4M | $51.1M |
| Weighted average diluted shares outstanding | $66M | $65.2M | $57.2M | $54.4M | $51.1M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $4.44B | $3.38B | $3.18B | $2.19B | $2.34B |
| Net receivables | $1.66B | $909.1M | $499.3M | $277.3M | $38.2M |
| Inventory | $473.5M | $407.2M | $310.6M | $228.4M | $109.1M |
| Total current assets | $6.9B | $4.88B | $4.12B | $2.77B | $2.54B |
| Property, plant and equipment, net | $48.3M | $43.5M | $22.7M | $16.2M | $15.8M |
| Goodwill and intangible assets | $272.1M | $181.4M | $125.2M | $174.9M | $171.7M |
| Long-term investments | $89.6M | $49.7M | $47.2M | $40.5M | $53.2M |
| Total non-current assets | $1.78B | $1.32B | $418.7M | $360.1M | $307.3M |
| Total assets | $8.68B | $6.2B | $4.54B | $3.13B | $2.85B |
| Accounts payable | $1.27B | $342.2M | $245.6M | $188.7M | $208.9M |
| Short-term debt | $10.8M | $6.53M | $4.65M | $3.42M | $3.51M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $1.32B | $669.9M | $423M | $302.3M | $301.2M |
| Long-term debt | $72.7M | $32.5M | $15.4M | $9.01M | $7.96M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $39.4M | $34.3M | $22M | $18.3M | $14.8M |
| Capital lease obligations | $36.3M | $32.5M | $15.4M | $9.01M | $7.96M |
| Total liabilities | $1.36B | $704.2M | $445M | $320.6M | $316.1M |
| Common stock | $7.35M | $6.98M | $6.39M | $6.64M | $6.23M |
| Retained earnings | -$-279.77M | -$-1.57B | -$-2.4B | -$-2.11B | -$-1.4B |
| Accumulated other comprehensive income (loss) | $73.6M | $66.7M | $72.1M | $71.7M | $465.4M |
| Total equity | $7.32B | $5.5B | $4.1B | $2.81B | $2.53B |
| Total investments | $1.04B | $1.93B | $1.18B | $1.43B | $1.06B |
| Total debt | $83.5M | $39.1M | $20M | $12.4M | $11.5M |
| Net debt | -$-3.41B | -$-1.46B | -$-2.03B | -$-788.31M | -$-1.32B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $1.05B | $833M | -$-425.05M | -$-720.34M | -$-348.75M |
| Depreciation and amortization | $28.1M | $17.5M | $111.3M | $104.3M | $5.87M |
| Stock-based compensation | $248.1M | $235.2M | $233M | $157M | $179.4M |
| Change in working capital | -$-423.94M | -$-324.6M | -$-308.89M | -$-375.93M | -$-340.95M |
| Accounts receivable | -$-804.81M | -$-422.36M | -$-185.69M | -$-222.26M | -$-31.63M |
| Inventory | -$-99.26M | -$-95.83M | -$-83.03M | -$-119.28M | -$-83.88M |
| Accounts payable | $614.2M | $245.9M | $0.00 | $0.00 | $0.00 |
| Net cash provided by operating activities | $850.5M | -$-82.75M | -$-420.33M | -$-862.81M | -$-606.81M |
| Investments in property, plant and equipment | -$-112.03M | -$-1.8M | -$-810K | -$-840K | -$-3.62M |
| Acquisitions, net | $0.00 | -$-7M | -$-13M | -$-2M | $0.00 |
| Net cash used for investing activities | $823.9M | -$-717.59M | $308.2M | -$-461.18M | -$-347.07M |
| Common stock issued | $279.2M | $308.7M | $1.2B | $761M | $1.12B |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $233.7M | $279.8M | $1.34B | $843.8M | $1.12B |
| Net change in cash | $1.99B | -$-548.91M | $1.25B | -$-533.94M | $117.9M |
| Cash at end of period | $3.49B | $1.5B | $2.05B | $800.7M | $1.33B |
| Operating cash flow | $850.5M | -$-82.75M | -$-420.33M | -$-862.81M | -$-606.81M |
| Capital expenditure | -$-6.18M | -$-68.3M | -$-43.81M | -$-103.82M | -$-121.43M |
| Free cash flow | $844.3M | -$-151.05M | -$-464.14M | -$-966.63M | -$-728.25M |
Line items
Line items
Line items
About argenx SE
argenx SE, a biotechnology company established in Amsterdam, the Netherlands, in 2008, is dedicated to developing innovative therapies primarily for autoimmune diseases. The company's operations span across key global markets, including the United States, Japan, Europe, the Middle East, Africa, and China. Its leading investigational therapy is efgartigimod, which is being developed to address a broad range of conditions. These include generalized myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary Sjögren's syndrome, post-COVID postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, ANCA-associated vasculitis, and antibody-mediated rejection. Also noted in connection with its lead product efforts is ENHANZE SC. The company's extensive development pipeline features several other promising candidates. Empasiprubart is in development for multifocal motor neuropathy, delayed graft function, and dermatomyositis. ARGX-119 is being investigated for congenital myasthenic syndrome and amyotrophic lateral sclerosis. Further pipeline assets include ARGX-213, which targets FcRn; ARGX-121 and ARGX-220, both designed to modulate the immune system; ARGX-109, which targets IL-6; and ARGX-118, developed for inflammatory indications. argenx is also advancing cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. The company’s portfolio encompasses several proprietary products and brands, such as VYVGART, VYVGART HYTRULO, VYVDURA, ARGENX, ABDEG, NHANCE, SIMPLE ANTIBODY, and ARGENXMEDHUB. Strategic collaborations are integral to argenx's business model. It maintains partnerships with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S, alongside numerous collaboration and license agreements with entities including Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. A specific collaboration with Genmab A/S focuses on the discovery, development, and commercialization of novel therapeutic antibodies for immunology and oncology applications. Additionally, argenx has a strategic collaboration with IQVIA Holdings Inc. for the provision of safety systems and related services.
- CEO
- Karen Massey
- Employees
- 1.86K
- Beta
- -0.02
Explore
Frequently asked questions
What is the intrinsic value of argenx SE (ARGX)?
argenx SE (ARGX) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is ARGX undervalued?
ARGX trades at a price of $925.70 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.